The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Cornered in a part of Downtown Los Angeles swamped in contemporary art museums and performance centers, REDCAT has become a ...

The lack of gains in productivity from AI could stall adoption and burst the economic bubble. Is there a rational explanation ...

A steaming bowl of pho becomes the most vivid thing in your visual field – the clear amber broth, bright green herbs, ruby red sriracha swirls, and sunny yellow lime wedges appearing almost ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...